Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma
Overview[ - collapse ][ - ]
| Purpose | A Phase II study of temsirolimus in combination with standard chemotherapy (irinotecan; cyclophosphamide, doxorubicin and etoposide (CAE); cisplatin and etoposide (HiPE) and topotecan (TPT) followed by and additional six courses of induction chemotherapy and then intensification with autologous hematopoietic stem cell transplantation. The first five courses of induction chemotherapy will also evaluate the feasibility of combining weekly temsirolimus with these standard chemotherapy combinations. This will be followed by 16 months of oral maintenance therapy with eight months of 13-cis-retinoic acid and then eight months of oral topotecan. |
|---|---|
| Condition | Neuroblastoma |
| Intervention | Drug: Temsirolimus Drug: Irinotecan Procedure: Surgical Resection of Primary Tumor Drug: Cyclophosphamide Drug: Doxorubicin Drug: Etoposide Drug: Cisplatin Drug: Topotecan Procedure: PBSC Radiation: Radiation Therapy Drug: 13-cis-retinoic acid |
| Phase | Phase 2 |
| Sponsor | St. Jude Children's Research Hospital |
| Responsible Party | St. Jude Children's Research Hospital |
| ClinicalTrials.gov Identifier | NCT00808899 |
| First Received | December 11, 2008 |
| Last Updated | May 25, 2010 |
| Last verified | May 2010 |
Tracking Information[ + expand ][ + ]
| First Received Date | December 11, 2008 |
|---|---|
| Last Updated Date | May 25, 2010 |
| Start Date | December 2008 |
| Estimated Primary Completion Date | July 2009 |
| Current Primary Outcome Measures | Complete Response Plus Partial Response [Time Frame: 10 years] [Designated as safety issue: Yes]The objective was to measure the efficacy and feasability of Temsirolimus and Irinotecan as measured by the objective response rate and toxicity rate. |
| Current Secondary Outcome Measures | Not Provided |
Descriptive Information[ + expand ][ + ]
| Brief Title | Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma |
|---|---|
| Official Title | Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma |
| Brief Summary | A Phase II study of temsirolimus in combination with standard chemotherapy (irinotecan; cyclophosphamide, doxorubicin and etoposide (CAE); cisplatin and etoposide (HiPE) and topotecan (TPT) followed by and additional six courses of induction chemotherapy and then intensification with autologous hematopoietic stem cell transplantation. The first five courses of induction chemotherapy will also evaluate the feasibility of combining weekly temsirolimus with these standard chemotherapy combinations. This will be followed by 16 months of oral maintenance therapy with eight months of 13-cis-retinoic acid and then eight months of oral topotecan. |
| Detailed Description | All children will receive fixed doses of intravenous temsirolimus (50 mg/m2 weekly 6 times ) concomitantly with two courses of fixed dosages of irinotecan (20 mg/m2 intravenously daily 5 times ,2 days off, repeated daily 5 times .If these initial dosages are not tolerable then subsequent patients will be given a reduced dosage of temsirolimus (25 mg/m2 weekly 6 times) with 20 mg/m2 of irinotecan.If this dosage combination is not tolerable, the irinotecan dosage will be decreased to 15 mg/m2 .If this dosage combination is not tolerable then further enrollment to the initial six week treatment will be terminated.The second course of irinotecan will begin on day 22 and response will be determined after six weeks (two courses). Resection of primary tumor will be attempted after this initial therapy, whenever possible. Following initial treatment children will undergo alternating courses of induction chemotherapy with cyclophosphamide, doxorubicin, etoposide, topotecan, and cisplatin (Block 2). The first cohort of 17 patients will receive Block 2 with temsirolimus (50mg/m2) for all three courses, weekly 2 times. If this is not tolerated subsequent patients will receive Block 2 chemotherapy with reduced dosages of temsirolimus (25mg/m2). |
| Study Type | Interventional |
| Study Phase | Phase 2 |
| Study Design | Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment |
| Condition | Neuroblastoma |
| Intervention | Drug: Temsirolimus Temsirolimus Drug: Irinotecan Irinotecan Procedure: Surgical Resection of Primary Tumor Surgical Resection of Primary Tumor Drug: Cyclophosphamide Cyclophosphamide Drug: Doxorubicin Doxorubicin Drug: Etoposide Etoposide Drug: Cisplatin Cisplatin Drug: Topotecan Topotecan Procedure: PBSC Peripheral Blood Stem Cell Harvest Radiation: Radiation Therapy Radiation Therapy Drug: 13-cis-retinoic acid 13-cis-retinoic acid |
| Study Arm (s) | Experimental: 1 Fixed doses of IV temsirolimus concomitantly with two courses of fixed dosages of irinotecan, 2 days off, repeated daily 5 times.If initial dosages are not tolerable, subsequent patients will be given a reduced dosage of temsirolimus with irinotecan.If this dosage combination is not tolerable,irinotecan dosage will be decreased.If this dosage combination is not tolerable.Further enrollment to initial six week treatment will be terminated.Second course of irinotecan will begin on day 22, response will be determined after six weeks. Resection of primary tumor will be attempted after initial therapy.Following initial treatment children will undergo alternating courses of induction chemotherapy with cyclophosphamide,doxorubicin,etoposide,topotecan, and cisplatin.First cohort of 17 patients will receive Block 2 with temsirolimus for all three courses, weekly 2 times.If this is not tolerated subsequent patients will receive Block 2 chemotherapy with reduced dosages of temsirolimus. |
Recruitment Information[ + expand ][ + ]
| Recruitment Status | Terminated |
|---|---|
| Estimated Enrollment | 4 |
| Estimated Completion Date | July 2009 |
| Estimated Primary Completion Date | July 2009 |
| Eligibility Criteria | Inclusion Criteria: - Patients <18 years old with newly diagnosed, advanced stage, high-risk neuroblastoma defined as one of the following: - Children < 1 yo with International Neuroblastoma Staging System (INSS) stage 2a, 2b, 3, 4 or 4S disease and MYCN amplification (>10 copies, or greater than four-fold increase in MYCN signal as compared to reference signal) - INSS 2a or 2b disease and MYCN amplification, regardless of age or additional biologic features - INSS stage 3 and: 1. MYCN amplification (>10 copies, or greater than four-fold increase in MYCN signal as compared to reference signal, regardless of age or additional biologic features 2. Age > 18 mo (> 547 days) with unfavorable pathology, regardless of MYCN status - INSS stage 4 and: 1. MYCN amplification, regardless of age or additional biologic features 2. Age > 18 months (> 547 days) regardless of biologic features 3. Age 12 - 18 months (365 - 547 days) with any of the following three unfavorable biologic features (MYCN amplification, unfavorable pathology and/or DNA index =1) or any biologic feature that is indeterminant/unknown - Children less than or equal to 365 days initially diagnosed with: INSS stage 1, 2, 4S who progressed to a stage 4 without interval chemotherapy. - Histologic proof of neuroblastoma or positive bone marrow for tumor cells with increased urine catecholamines. - Adequate renal and hepatic function (serum creatinine <3 x upper limit of normal for age, (AST) aspartate aminotransferase < 3 x upper limit of normal). - No prior therapy, unless an emergency situation requires local tumor treatment (discuss with PI) - Written, informed consent according to institutional guidelines Exclusion Criteria: - Any evidence, as judged by the investigator, of severe or uncontrolled systemic disease (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease). - Pregnant or breast feeding (women of child-bearing potential). - Children with INSS 4 disease, age <12 months with all 3 favorable biologic features (non-amplified MYCN, favorable pathology and DNA index >1). |
| Gender | Both |
| Ages | N/A |
| Accepts Healthy Volunteers | No |
| Contacts | Not Provided |
| Location Countries | United States |
Administrative Information[ + expand ][ + ]
| NCT Number | NCT00808899 |
|---|---|
| Other Study ID Numbers | NB2008 |
| Has Data Monitoring Committee | No |
| Information Provided By | St. Jude Children's Research Hospital |
| Study Sponsor | St. Jude Children's Research Hospital |
| Collaborators | Not Provided |
| Investigators | Principal Investigator: Wayne L Furman, MD St. Jude Children's Research Hospital |
| Verification Date | May 2010 |
Locations[ + expand ][ + ]
| St. Jude Children's Research Hospital | Memphis, Tennessee, United States, 38105 |
|---|